The FDA granted accelerated approval to zanubrutinib for the treatment of adult patients with MCL who have received at least 1 prior therapy.
Mantle Cell Lymphoma
Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.
Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.
A retrospective study finds that younger mantle cell lymphoma patients may achieve longer PFS with AHCT consolidation.
This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.
This video reviews the treatment of mantle cell lymphoma cases that do not fit the typical mold.
The FDA has granted accelerated approval to acalabrutinib (Calquence) for the treatment of mantle cell lymphoma in adult patients who have received at least one previous therapy.
Maintenance therapy with rituximab following autologous stem cell transplantation prolonged progression-free, event-free, and overall survival compared with observation in patients with mantle cell lymphoma, according to a new study.
This video reviews different strategies for maintenance therapy in mantle cell lymphoma, as well as highlighting upcoming research in this setting.
Management strategies for patients with mantle cell lymphoma continue to demonstrate pendulum-like swings between those appropriate for low-grade lymphoma, and those appropriate for very aggressive lymphoma.